Newly-listed shares gain; Bluestone up 14%, Anthem Biosciences, Prostarm rise up to 10%

Newly listed shares gain; Bluestone up 9%, Anthem Biosciences, Prostarm rise up to 10%.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Bluestone Jewellery shares surged more than 14 percent in Wednesday's trading session to an intraday high of Rs 625 per share on the NSE. Later, at around 3 p.m., the stock pared some of the gains to quote at Rs 574.3 apiece up 5.18 percent.

Shares of BlueStone Jewellery and Lifestyle Ltd, which offers contemporary jewellery under its flagship brand 'BlueStone', on August 19 ended with a premium of nearly 6 percent against the issue price of Rs 517.

The stock started trading at Rs 508.80, down 1.58 percent from the issue price on the BSE. However, later, it bounced back and climbed 9 percent to Rs 564 in intra-day trade. The stock finally ended at Rs 546, up 5.60 per cent. On the NSE, the stock listed at Rs 510, a discount of 1.35 percent. Shares of the firm later recovered the early lost ground and went up by 9 percent to hit the day's high of Rs 564. The stock ended at Rs 546, a jump of 5.60 per cent.

Meanwhile, shares of Prostarm Info Systems hit the 10 percent upper circuit on August 20, amid high volume trading in the counter.

The shares of Prostarm Info Systems were listed on BSE at Rs 125 apiece on June 3, marking a premium of 19.05 percent over the IPO price of Rs 105 apiece. The company debuted with a market capitalization of over Rs 707 crore.

Anthem BioSciences shares also surged 3 percent amid high volume to Rs 842 per share on the NSE.

Its shares listed on the stock exchanges on July 21 with a premium of about 27 percent over it's initial public offer (IPO) price. The Rs 3,395-crore public offer was priced in the band of Rs 540-570 per share, and received strong investor interest with about 64 times subscription during the offer period from July 14 to 16.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.